Table 2.

Relationships between Neurocognitive Performance and Variables of Interest for HIV-infected Subjects.

A. Correlations between Neurocognitive Performance and Variables of Interest
Variable	Verbal Comprehension		Perceptual Reasoning		Working Memory		Processing Speed		Full-Scale IQ
Age	R* = 0.21; P = 0.16		R = 0.003; P = 0.99		R = 0.13; P = 0.40		R = −0.004; P = 0.98		R = 0.16; P = 0.31
HIV duration	R = −0.39; P = 0.01		R = −0.30; P = 0.05		R = −0.42; P = 0.005		R = −0.26; P = 0.10		R = −0.44; P = 0.003
ART duration	R = −0.25; P = 0.11		R = −0.22; P = 0.17		R = −0.37; P = 0.02		R = −0.14; P = 0.37		R = −0.33; P = 0.03
CD4 nadir	R = 0.002; P = 0.99		R = −0.03; P = 0.88		R = −0.19; P = 0.24		R = −0.02; P = 0.88		R = −0.03; P = 0.86
% CD4+CD38+HLA-DR+a	R = −0.33; P = 0.03		R = −0.03; P = 0.85		R = −0.02; P = 0.89		R = −0.23; P = 0.14		R = −0.21; P = 0.17
% CD8+CD38+HLA-DR+b	R = −0.22; P = 0.17		R = 0.22; P = 0.16		R = 0.12; P = 0.45		R = −0.002; P = 0.89		R = −0.04; P = 0.79
% CD14+CD16+c	R = −0.04; P = 0.79		R = 0.01; P = 0.96		R = 0.20; P = 0.20		R = 0.20; P = 0.20		R = 0.10; P = 0.66
% CD14dimCD16+d	R = 0.05; P = 0.76		R = −0.004; P = 0.98		R = −0.05; P = 0.77		R = −0.01; P = 0.97		R = −0.01; P = 0.96
sCD14, ng/mLe	R = −0.37; P = 0.01		R = −0.14; P = 0.36		R = −0.16; P = 0.28		R = −0.15; P = 0.32		R = −0.30; P = 0.04
sCD16, ng/mLe	R= −0.25; P = 0.11		R = 0.04; P = 0.80		R = −0.15; P = 0.34		R = −0.28; P = 0.85		R = −0.15; P = 0.32
B. Differences in Neurocognitive Performance in Sub-groups Based on Dichotomous Variables
Variable	Verbal Comprehension		Perceptual Reasoning		Working Memory		Processing Speed		Full-Scale IQ
	Median (Q1, Q3)	P	Median (Q1, Q3)	P	Median (Q1, Q3)	P	Median (Q1, Q3)	P	Median (Q1, Q3)	P
Male	92 (81, 100)	0.006	91 (84, 104)	0.004	89 (77, 105)	0.28	102 (96, 127)	0.91	89 (84, 98)	0.02
Female	81 (72, 89)		79 (75, 90)		89 (74, 97)		100 (81, 102)		84 (72, 88)
Black race	89 (80, 96)	0.63	87 (78, 101)	0.25	89 (77, 99)	0.50	94 (84, 102)	0.03	87 (77, 94)	0.52
Non-black race	77 (74, 96)		94 (92, 94)		97 (89, 102)		105 (100, 106)		86 (85, 99)
Perinatal transmission	81 (74, 95)	0.02	86 (75, 98)	0.24	86 (74, 97)	0.02	94 (89, 100)	0.23	85 (75, 89)	0.02
Horizontal transmission	91 (81, 102)		90 (82, 104)		96 (86, 105)		99 (84, 105)		94 (84, 102)
Prior AIDS diagnosis	82 (74, 96)	0.50	88 (75, 94)	0.45	87 (86, 105)	0.34	100 (89, 102)	0.89	86 (75, 98)	0.49
No prior AIDS diagnosis	89 (80, 96)		88 (82, 104)		89 (77, 99)		97 (84, 102)		88 (77, 95)
Marijuana use	94 (81, 104)	0.21	90 (86, 106)	0.21	102 (89, 105)	0.04	107 (100, 119)	0.01	97 (88, 108)	0.04
No marijuana use	83 (76, 95)		86 (77, 98)		89 (77, 97)		94 (84, 100)		86 (77, 92)

^*Spearman correlation coefficient;

^a% of CD4+ T-cells expressing CD38 and HLA-DR;

^b% of CD8+ T-cells expressing CD38 and HLA-DR;

^c% of monocytes expressing CD14+CD16+;

^d% of monocytes expressing CD14dimCD16+;

^ePlasma concentration of sCD14 and sCD16, respectively.

Bold-faced numbers indicate P values <0.05. HIV, human immunodeficiency virus; IQ, intelligence quotient; ART, antiretroviral therapy; sCD14, soluble CD14